REMARKS

Claims 82-118 are pending.

Formula (A) at page 6 of the specification, respectively, have been amended to correct

the number of R⁶ groups. As described in the specification, three of the Qs may be a nitrogen

atom. Therefore, the minimum number of R⁶ groups is 1 (when 3 Os are nitrogen atoms) and

the maximum number of R⁶ groups is 4 (when none of the Qs are nitrogen atoms). Formula

(A) has been amended to correctly show 1-4 R⁶ groups. The bottom of page 7 and page 15

have been amended to correct a typographical error. As shown in formula (A), there are no

R⁵ groups substituting the Qs in the ring. In addition, a revised Abstract has been submitted

to make the corresponding change to formula (A).

Claim 82 has been amended to specify 3 R⁶ groups in formula (A) in view of the

remarks above, i.e., because one Q is a nitrogen atom. The definition of Q has also been

amended to reflect the changes made to the specification discussed above.

In addition, Claim 116 has been amended to specify a P2Y2 receptor agonist. That

amendment is supported by the specification at page 20, line 10.

No new matter is believed to have been added to this application by the amendments

submitted above.

Applicants submit that the present application is ready for examination on the merits.

Early notice to this effect is earnestly solicited.

Respectfully submitted,

Customer Number

22850

Tel: (703) 413-3000 Fax: (703) 413 -2220

(OSMMN 06/04)

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

James J. Kelly, Ph.D.

Attorney of Record

Registration No. 41,504

JK\la

12